Understanding heart problems caused by cancer treatments
Official title: Unraveling Proteasome Inhibitor-Induced Cardiovascular Toxicity through Integrative Multiomics
Funded at Stanford University · NIH-11023940 · Data updated 2026-11-12
This study is looking at how certain cancer treatments called proteasome inhibitors might affect heart health, and it's for patients who are receiving these therapies; researchers want to understand the heart changes caused by these drugs so they can help make cancer treatments safer for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $717,246 |
| NIH project number | 1R01HL176822-01 |
| Project ID | NIH-11023940 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing treatment with proteasome inhibitors, particularly those with hematologic malignancies.
✕Less likely to help
Patients not receiving proteasome inhibitors or those without cardiovascular concerns may not benefit from this research.
What this research studies
This research investigates how proteasome inhibitors, a type of cancer treatment, can lead to heart-related side effects. Using advanced techniques like CRISPR technology and single-cell RNA sequencing, the study aims to identify the molecular changes in heart cells caused by these drugs. By examining both mouse models and human stem cells, researchers hope to uncover the mechanisms behind cardiovascular toxicity and explore potential ways to prevent it. The ultimate goal is to improve the safety of cancer therapies for patients who need them.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments with fewer heart-related side effects.
How similar studies have gone: Other research has shown promise in understanding drug-induced toxicity through similar molecular approaches, indicating potential for success in this area.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Wu, Joseph C. — Stanford University
- Study coordinator: Wu, Joseph C.
Related research
Other NIH-funded projects on the same topics.
-
Multimodal AI to predict CAR-T patient response and guide safer, smarter cell design
A Stanford team is building AI tools that use patient and CAR-T cell data to predict how well a CAR-T therapy will work and what design changes might boost effectiveness and safety for people with cancer.
-
Community-driven model to reduce overdose deaths through smarter resource use
A Stanford-led project uses a data-driven model to help counties pick the best ways to prevent opioid and stimulant overdoses and save lives.
-
Center for Dissemination and Implementation at Stanford: Research Core
A Stanford-based program is advancing how evidence-based addiction treatments are implemented across settings to help people with substance use disorders receive better care.
-
Center for Dissemination and Implementation At Stanford (C-DIAS)
A center-based program at Stanford aims to speed people who need addiction treatments to get evidence-based care.
-
Mitochondrial structure and neuron health in Alzheimer's and ALS
This grant studies how mitochondrial cristae structure in neurons is controlled and how its disruption may contribute to diseases like Alzheimer's and ALS.
-
Pediatric EMS seizures: simpler age-based midazolam dosing
A nationwide trial at EMS agencies tests whether using fixed, age-based dosing of midazolam for seizures in children improves treatment speed and safety.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.